Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.950
+0.120 (6.56%)
Sep 5, 2025, 4:00 PM EDT
6.56%
Market Cap105.84M
Revenue (ttm)65.29K
Net Income (ttm)-8.49M
Shares Out54.28M
EPS (ttm)-0.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,150
Average Volume35,967
Open1.880
Previous Close1.830
Day's Range1.880 - 1.950
52-Week Range0.900 - 2.380
Betan/a
RSI53.92
Earnings DateSep 18, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.